Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   GNBT

Amerikaanse aandelen« Terug naar discussie overzicht

GNBT

Volgen
917 Posts
Pagina: «« 1 ... 38 39 40 41 42 ... 46 »» | Laatste | Omlaag ↓
  1. ressiva 8 juli 2009 09:30
    GNBT has made a golden cross
    the 50MA crossing the 200 MA
    The chart is extremely bullish.
    The 50 MA is being tested and is holding fine.Don't forget this stock need a lot of volume: study the chart
    :Investopedia explains Golden Cross
    As long-term indicators carry more weight, the Golden Cross indicates a bull market on the horizon and is reinforced by high trading volumes. Additionally, the long-term moving average becomes the new support level in the rising market.

    Technicians might see this cross as a sign that the market has turned in favor of the stock.

  9. [verwijderd] 9 juli 2009 14:14
    quote:

    ressiva schreef:

    Koers staat nota bene lager dan Pharming, terwijl van GNBT al diverse producten zijn goedgekeurd. Absurd! Op naar de oude 1,14!
    Heb er hier ook een paar van gekocht gisteren.
    Voorbeurs ziet er aardig uit, maar dat was gister ook zo, hopen dus dat ie doorzet:

    0.59
    Last Trade 0.0291 (+5.19%)
  11. [verwijderd] 17 juli 2009 16:19
    Heb net een klein plukje gekocht op 0,58. Ze zijn bezig om de markt op te gaan in Europa, in ieder geval met hun spray tegen de lekkere (snack-)trek.
    De Crave Nx dietspray zal een leadingproduct zijn denk ik op de vrije markt.

    Spoedig meer info als het goed is. Nieuws komt dan uit Dubai...van daaruit wordt Europa bediend en voorzien van de producten van Generex.

    Longterm kan geen kwaad denk ik.
  12. [verwijderd] 17 juli 2009 19:23
    quote:

    marnop schreef:

    Heb net een klein plukje gekocht op 0,58. Ze zijn bezig om de markt op te gaan in Europa, in ieder geval met hun spray tegen de lekkere (snack-)trek.
    De Crave Nx dietspray zal een leadingproduct zijn denk ik op de vrije markt.

    Spoedig meer info als het goed is. Nieuws komt dan uit Dubai...van daaruit wordt Europa bediend en voorzien van de producten van Generex.

    Longterm kan geen kwaad denk ik.
    zelf al een paar dagen wat aan het kopen hierin

    technisch,niet op fundamentals, maar puur TA
    zou 1,50-2,00 in vat kunnen zitten

    nu strakke consolidatie
  16. [verwijderd] 20 juli 2009 22:43
    Ik kreeg een mailtje van Generex dat ik dit stukje mogelijk interessant zou vinden.
    het serieuze adverteren is begonnen :
    bron : www.mydesert.com/apps/pbcs.dll/articl...

    How to spritz your hunger, cravings away
    Barbara Lowell • The Desert Sun • July 2, 2009

    Say you're at work, and someone has brought in a box of doughnuts, or baked a batch of cookies to share.

    You're trying to stick to your diet, but you didn't have breakfast, and now you REALLY want one or two or half a dozen of those cookies.

    Will power is one thing. Ignoring the gnawing hunger in your stomach is something else.

    That's where Crave-NX can help. It's a “scientifically formulated oral glucose spray” that's made to quell cravings without extra calories — a “serving” of spray into the mouth contains just 2 calories.

    Does it work? Yes.

    We tried the orange flavor, which has a sweet/bitter combination taste that's sort of like biting into an orange peel. It immediately went to work on the cravings, and left a lingering taste, sort of like the feeling you get after you chew a glob of gum or eat a piece of fruit candy.

    It did the trick. OK, you won't feel as satisfied as if you'd eaten aforementioned cookies, but it does curb the hunger — the spray staved off cravings for about an hour, until we were able to eat a healthy lunch.

    The FDA-approved product is not recommended as a meal replacement, but rather an instant helper to shave calories from your daily food intake.

    The company has done the math and printed their findings on the box: if you can save 250 calories from your diet each day, that will equal 91,250 calories, or a loss of 26 pounds. Works for me!

    Cost for the .64-ounce spray bottle (small enough to slip into your purse or pocket) starts at $6.99 in drug and discount department stores, or $7.99 at the company's Web site, www.crave-nx.com
  19. [verwijderd] 21 juli 2009 14:44

    Eén vd betere op YB:

    It is slowly emerging that Antigen's AE37 is a significant medical breakthrough for the treatment of cancer and viral diseases. Consider:

    - Dr Constantin G. Ioannides, a third party authority in cancer research using and proving the benefit of Antigen's AE37 compound in treating breast cancer.

    - Dr George Peoples, another authority on cancer research, conducting breast cancer Phase II using AE37.

    - Dr John Treanor, a world renowned authority in viral influenza research using Antigen's AE37 to combat bird flu and swine flu diseases.

    - AE37 can be used to as a vaccine on its own merit or used to enhance the effectiveness of existing vaccines or drugs like Aphtera's E75. Consider the many potential usages of AE37.

    How long before companies knocking at Generex's door for licensing AE37? How long before the rest of the world discover the potential good

    As far as I am concerned, we are literally sitting on a gold mine with Generex. I suggest you put all the bashers and shorts on ignore. They are but a distraction. They will disappear when GNBT makes the same move as DNDN once the rest of the world knows about Generex' Antigen. Breast cancer PII trials have been going on and results are due by end of the year.

    Check the impressive credentials of the doctors using Antigen AE37:

    Dr. Ioannides is a well-known and highly respected cancer immunologist with over a hundred peer-reviewed articles in the scientific literature. He currently serves as Professor of Immunology at M. D. Anderson Cancer Center (MDACC). Dr. Ioannides has been involved with some of the most important advancements in the field of cancer immunology over the past 20 years. He is the co-discoverer of the NeuVax™ (E75) vaccine. Drs. Ioannides and Peoples work at MDACC resulted in the discovery of the FBP vaccine, its formulation, and delivery.

    Dr. Peoples is a clinician and the co-inventor of the core technology. Dr. Peoples has been named to direct the newly created United States Military Cancer Institute’s Clinical Trials Program which is headquartered at Brooke Army Medical Center in Ft. Sam Houston, TX. Dr. Peoples previously served as Chief of Surgical Oncology at Walter Reed Army Medical Center (WRAMC). He continues to serve as the Director of the Cancer Vaccine Development Laboratory at the Uniformed Services University of the Health Sciences. Dr. Peoples obtained his medical degree from Johns Hopkins School of Medicine after completing his undergraduate studies at the United States Military Academy, West Point. He received his surgical training at Harvard Medical School’s (HMS) Brigham and Women’s Hospital. He completed a 3-year research fellowship in the Laboratory of Biologic Cancer Therapy at HMS where he co-discovered HER2/neu vaccines.

    Dr. Treanor received his MD degree from the University of Rochester in Rochester NY and Internal Medicine internship and residency training at the University of Vermont, in Burlington, Vermont. He then did clinical and research training in Infectious Diseases at the University of Rochester and in the Laboratory of Infectious Diseases, NIH, Bethesda MD. Since 1988 Dr. Treanor has been a member of the Infectious Diseases Unit at the University of Rochester, where he directs the Vaccines and Treatments Evaluation Unit (VTEU). Dr. Treanor’s primary research interests include clinical virology and clinical trials, especially related to clinical evaluation of novel vaccines for influenza. Current projects are related to candidate pandemic vaccines, approaches to intranasal vaccination using live or inactivated vaccines, and use of expressed recombinant proteins as vaccines.

    Who have more credibility, the lowly bashers on a yahoo message board or these three doctors? You decide.
917 Posts
Pagina: «« 1 ... 38 39 40 41 42 ... 46 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Heineken 76,420 +8,46 +12,45%
ABN AMRO BANK N.V. 17,620 +1,11 +6,72%
TomTom 4,174 +0,18 +4,45%
WDP 21,120 +0,60 +2,92%
ALLFUNDS GROUP 4,994 +0,13 +2,67%
Flow Traders 24,300 +0,50 +2,10%
JDE PEET'S 16,570 +0,32 +1,97%
CTP 16,760 +0,32 +1,95%
Wereldhave 16,320 +0,30 +1,87%
NX FILTRATION 3,065 +0,06 +1,83%
PROSUS 40,465 +0,67 +1,68%
AMG Critical Materials N.V. 15,750 +0,21 +1,35%
Van Lanschot Kempen NV 49,050 +0,65 +1,34%
HEIJMANS KON 32,300 +0,40 +1,25%
Eurocommercial Properties 24,700 +0,25 +1,02%
Accsys 0,509 +0,01 +0,99%
Akzo Nobel 56,800 +0,54 +0,96%
Avantium 1,760 +0,02 +0,92%
Galapagos 22,520 +0,18 +0,81%
ASR Nederland 47,930 +0,37 +0,78%
PostNL 1,037 +0,01 +0,78%
ING 16,144 +0,12 +0,74%
CM.COM 6,880 +0,05 +0,73%
NN Group 44,930 +0,32 +0,72%
EXOR NV 94,200 +0,65 +0,69%
AMX 853,38 +5,65 +0,67%
Pharming 0,848 +0,01 +0,65%
Fagron 19,520 +0,12 +0,62%
ForFarmers 3,420 +0,02 +0,59%
ADYEN NV 1.560,000 +9,00 +0,58%
Philips Koninklijke 27,080 +0,15 +0,56%
ACOMO 18,420 +0,10 +0,55%
Aegon 6,462 +0,03 +0,53%
KPN 3,548 +0,02 +0,51%
IMCD 149,550 +0,75 +0,50%
UMG 28,000 +0,14 +0,50%
ASCX 1.284,46 +6,22 +0,49%
INPOST 16,400 +0,07 +0,43%
JUST EAT TAKEAWAY 12,655 +0,05 +0,36%
VASTNED 28,400 +0,10 +0,35%
AALBERTS NV 34,900 +0,12 +0,35%
TKH 36,520 +0,12 +0,33%
BAM 4,232 +0,01 +0,28%
Arcadis 54,050 +0,15 +0,28%
UNILEVER PLC 56,920 +0,14 +0,25%
RELX 49,560 +0,12 +0,24%
ArcelorMittal 26,720 +0,04 +0,15%
AZERION 1,668 +0,00 +0,12%
AEX 939,53 +0,61 +0,06%
Kendrion 10,360 0,00 0,00%
NSI 22,350 0,00 0,00%
SIGNIFY NV 20,760 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Ahold Delhaize 33,970 -1,71 -4,79%
Alfen N.V. 13,255 -0,50 -3,64%
RANDSTAD NV 40,100 -1,35 -3,26%
EBUSCO HOLDING 0,731 -0,02 -3,25%
BESI 114,050 -1,70 -1,47%
Aperam 27,840 -0,40 -1,42%
Nedap N.V. 59,800 -0,80 -1,32%
Fugro 14,280 -0,14 -0,97%
ASML 716,900 -6,70 -0,93%
ASMI 565,200 -5,00 -0,88%
RENEWI 9,490 -0,08 -0,84%
Sif Holding 12,120 -0,10 -0,82%
SHELL PLC 32,365 -0,25 -0,77%
SBM Offshore 18,350 -0,12 -0,65%
DSM FIRMENICH AG 99,900 -0,60 -0,60%
Vopak 44,540 -0,24 -0,54%
Corbion 22,420 -0,12 -0,53%
FASTNED 20,300 -0,10 -0,49%
OCI 10,935 -0,05 -0,46%
B&S Group SA 4,175 -0,02 -0,36%
Brunel 9,430 -0,03 -0,32%
Sligro 10,700 -0,02 -0,19%
Basic-Fit 22,440 -0,04 -0,18%
Air France-KLM 8,188 -0,01 -0,17%
THEON INTERNAT 14,940 -0,02 -0,13%
Wolters Kluwer 180,100 -0,15 -0,08%
vlag naam koers verschil relatief verschil
AEX 939,53 +0,61 +0,06%
AEX GR 3.689,67 +6,01 +0,16%
DE40-DAX 22.037,83 0,00 0,00%
FTSE 100 8.782,89 +5,50 +0,06%
Europe50^ 5.390,91 0,00 0,00%
US30^ 44.550,20 -64,90 -0,15%
Nasd100^ 21.693,30 -8,40 -0,04%
US500^ 6.063,56 -7,88 -0,13%
Japan225^ 39.030,80 -56,00 -0,14%
VD-NEW 16,78 -0,24 -1,39%
#/^ Index indications calculated real time, zie disclaimer